Drug Trial Radar · NCT01901432
A Two-part Study to Assess the Safety and Preliminary Efficacy of Givinostat in Patients With Polycythemia Vera
Last checked: Nov 19, 2026Latest source record: Jul 30, 2019 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
48
Actual
Start
Oct 2013
Primary completion
Jun 26, 2017
Study completion Sep 25, 2017
Sponsor
- Lead sponsor
- ItalfarmacoIndustry
- Sponsor type
- Industry
- First posted
- Jul 17, 2013
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a two-part, multicenter, open label, non-randomized, phase Ib/II study to assess the safety and tolerability, Maximum Tolerated Dose and preliminary efficacy of Givinostat in patients with JAK2V617F positive Polycythemia Vera. Part A is the dose finding part while Part B is assessing the preliminary efficacy. Patients will be enrolled either in Part A or Part B and transition from one part to the other is not allowed. Eligible patients for this study will have a confirmed diagnosis of Polycythemia Vera according to the revised World Health Organization criteria. Only if the enrolment in Part A is slow (i.e. \< 5 patients enrolled in 3 months), eligibility for this part of the study may be expanded to all patients with chronic myeloproliferative neoplasms. Study therapy will be administered in 28 day cycles (4 weeks of treatment). Disease response will be evaluated according to the European LeukemiaNet criteria after 3 and 6 cycles (i.e. at weeks 12 and 24, respectively) of treatment with Givinostat for both parts of the study. All phlebotomies performed in the first 3 weeks of treatment will not be counted to assess the clinico-haematological response. The study will last up to a maximum of 24 weeks of treatment. However, after completion of the trial, all patients achieving clinical benefit will be allowed to continue treatment with Givinostat (at the same dose and schedule) in a long-term study. Safety will be monitored at each visit throughout the entire duration of the study. Treatment will be administered on an outpatient basis and patients will be followed regularly with physical and laboratory tests, as specified in the protocol; in case of hospitalization, the treatment will be continued or interrupted according to the Investigators' decision.
Conditions
- Polycythemia Vera
Interventions
GivinostatDrug
In Part A patients will treated in dose levels at the following daily doses of Givinostat: * 50 mg b.i.d., * 100 mg b.i.d.; * 150 mg b.i.d., * 200 mg b.i.d.; * 150 mg t.i.d.; * 200 mg t.i.d.. Intermediate dose levels and, consequently, additionally dose levels may be used to establish the Maximum Tolerated Dose. In Part B patients will be treated at the Maximum Tolerated Dose established in Part A. The product will be supplied as hard gelatine capsules for oral administration at the strength of 50 mg, 75 mg and/or 100 mg each.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Patients Experiencing Treatment-emergent Adverse Events (TEAEs) in Part A of the StudyTime frame: 168 days (up to Cycle 6 Day 28 in Part A).
- Number of Dose Limiting Toxicities (DLTs) After 1 Cycle in Part A of the StudyTime frame: 28 days (up to Cycle 1 Day 28 in Part A).
- Number of Patients Experiencing TEAEs After 3 Cycles in Part B of the StudyTime frame: 84 days (up to Cycle 3 Day 28 in Part B).
- Overall Response Rate (ORR) (i.e. Complete Response [CR] and Partial Response [PR]) After 3 Cycles in Part B of the StudyTime frame: 84 days (up to cycle 3 Day 28 in Part B).
Locations
25 sites in 5 countries. Site status is shown where the registry gives one.
CHU Amiens - Hôpital Sud
Amiens, France
Hôpital Morvan - CHRU de Brest
Brest, France
Hopital Saint Vincent de Paul - GHICL Lille
Lille, France
Hôpital Saint-Louis (AP-HP), Centre Investigations Cliniques
Paris, France
Charite Research Organisation GmbH
Berlin, Germany
Universitaetsklinikum Koeln
Cologne, Germany
Universitaetsklinikum Carl Gustav Carus TU Dresden
Dresden, Germany
Universitaetsklinikum Freiburg
Freiburg im Breisgau, Germany
Istituto Tumori Giovanni Paolo II - IRCCS Ospedale Oncologico di Bari
Bari, Italy
Fondazione IRCCS Cà Granda, Ospedale Maggiore Policlinico
Milan, Italy
Università degli Studi di Napoli Federico II, Facoltà di Medicina e Chirurgia
Naples, Italy
Ospedale Civile dello Spirito Santo
Pescara, Italy
Azienda Ospedaliero Universitaria Pisana
Pisa, Italy
Azienda Ospedaliera "Bianchi-Melacrino-Morelli"
Reggio Calabria, Italy
Università Campus Bio-Medico di Roma
Rome, Italy
Ospedale San Bortolo di Vicenza
Vicenza, Italy
Azienda ospedaliero universitaria Consorziale Policlinico di Bari
Bari, BA, Italy
Azienda Ospedaliera Papa Giovanni XXIII
Bergamo, BG, Italy
Azienda Ospedaliero-Universitaria Careggi, Florence
Florence, FI, Italy
Fondazione IRCCS Policlinico San Matteo
Pavia, PV, Italy
SP ZOZ Zespol Szpitali Miejskich w Chorzowie
Chorzów, Poland
Uniwersyteckie Centrum Kliniczne
Gdansk, Poland
Belfast City Hospital
Belfast, United Kingdom
Royal London Hospital
London, United Kingdom
Royal Cornwall Hospital
Truro, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.